ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C

Open source

DOI
10.1007/s00277-024-05665-4
Published
2024 Jul
Container
Annals of hematology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00277-024-05665-4,
  title = {ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.},
  author = {Kiladjian JJ and Marin FF and Al-Ali HK and Alvarez-Larrán A and Beggiato E and Bieniaszewska M and Breccia M and Buxhofer-Ausch V and Cerna O and Crisan AM and Danaila CD and De Stefano V and Döhner K and Empson V and Gora-Tybor J and Griesshammer M and Grosicki S and Guglielmelli P and García-Gutierrez V and Heidel FH and Illés A and Tomuleasa C and James C and Koschmieder S and Krauth MT and Krejcy K and Lazaroiu MC and Mayer J and Nagy ZG and Nicolini FE and Palandri F and Pappa V and Reiter AJ and Sacha T and Schlager S and Schmidt S and Terpos E and Unger M and Wölfler A and Cirici BX and Klade C},
  year = {2024},
  journal = {Annals of hematology},
  doi = {10.1007/s00277-024-05665-4},
  url = {https://doi.org/10.1007/s00277-024-05665-4}
}

RIS

TY  - JOUR
TI  - ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
AU  - Kiladjian JJ
AU  - Marin FF
AU  - Al-Ali HK
AU  - Alvarez-Larrán A
AU  - Beggiato E
AU  - Bieniaszewska M
AU  - Breccia M
AU  - Buxhofer-Ausch V
AU  - Cerna O
AU  - Crisan AM
AU  - Danaila CD
AU  - De Stefano V
AU  - Döhner K
AU  - Empson V
AU  - Gora-Tybor J
AU  - Griesshammer M
AU  - Grosicki S
AU  - Guglielmelli P
AU  - García-Gutierrez V
AU  - Heidel FH
AU  - Illés A
AU  - Tomuleasa C
AU  - James C
AU  - Koschmieder S
AU  - Krauth MT
AU  - Krejcy K
AU  - Lazaroiu MC
AU  - Mayer J
AU  - Nagy ZG
AU  - Nicolini FE
AU  - Palandri F
AU  - Pappa V
AU  - Reiter AJ
AU  - Sacha T
AU  - Schlager S
AU  - Schmidt S
AU  - Terpos E
AU  - Unger M
AU  - Wölfler A
AU  - Cirici BX
AU  - Klade C
PY  - 2024
JO  - Annals of hematology
DO  - 10.1007/s00277-024-05665-4
UR  - https://doi.org/10.1007/s00277-024-05665-4
ER  -

APA

JJ, K., FF, M., HK, A., A, A., E, B., M, B., M, B., V, B., O, C., AM, C., CD, D., V, D. S., K, D., V, E., J, G., M, G., S, G., P, G., V, G., FH, H., A, I., C, T., C, J., S, K., MT, K., K, K., MC, L., J, M., ZG, N., FE, N., F, P., V, P., AJ, R., T, S., S, S., S, S., E, T., M, U., A, W., BX, C., & C, K. (2024). ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.. Annals of hematology. https://doi.org/10.1007/s00277-024-05665-4

Source records